MARCHIGNOLI, FRANCESCA
 Distribuzione geografica
Continente #
NA - Nord America 252
EU - Europa 218
AS - Asia 56
AF - Africa 12
SA - Sud America 1
Totale 539
Nazione #
US - Stati Uniti d'America 251
IT - Italia 81
GB - Regno Unito 42
DE - Germania 26
SE - Svezia 21
CN - Cina 15
IN - India 14
SG - Singapore 14
IE - Irlanda 12
BG - Bulgaria 8
RU - Federazione Russa 7
CI - Costa d'Avorio 6
FI - Finlandia 5
FR - Francia 5
TR - Turchia 5
EE - Estonia 3
JO - Giordania 3
ZA - Sudafrica 3
LB - Libano 2
RS - Serbia 2
TG - Togo 2
AT - Austria 1
BD - Bangladesh 1
BE - Belgio 1
CA - Canada 1
CH - Svizzera 1
EC - Ecuador 1
ID - Indonesia 1
NG - Nigeria 1
NL - Olanda 1
NO - Norvegia 1
PK - Pakistan 1
RO - Romania 1
Totale 539
Città #
Southend 37
Bologna 28
Fairfield 28
Ashburn 26
Chandler 22
Seattle 16
Princeton 14
Boardman 12
Dublin 12
Houston 11
Singapore 10
Cambridge 9
Sofia 8
Wilmington 8
Woodbridge 8
Milan 7
Turin 7
Abidjan 6
Naples 6
Ankara 5
Berlin 4
Helsinki 4
Trento 4
Amman 3
Ann Arbor 3
Boydton 3
Leuna 3
Olalla 3
Padova 3
Rimini 3
Riva del Garda 3
Westminster 3
Hebei 2
Lomé 2
London 2
Lucknow 2
Medford 2
Munich 2
Nanchang 2
New York 2
Rome 2
San Diego 2
San Francisco 2
Shenyang 2
Zrenjanin 2
Abeokuta 1
Beijing 1
Brussels 1
Buffalo 1
Cesena 1
Changsha 1
Chicago 1
Chongqing 1
Clearwater 1
Cuenca 1
Dearborn 1
Den Haag 1
Des Moines 1
Dhaka 1
Frankfurt am Main 1
Gloucester 1
Haikou 1
Hendon 1
Hyderabad 1
Islamabad 1
Jinan 1
Lapio 1
Lappeenranta 1
Malang 1
Norwalk 1
Omsk 1
Paris 1
Parma 1
Pitesti 1
Pune 1
Qingdao 1
Redmond 1
Saint Petersburg 1
San Jose 1
Sesto San Giovanni 1
Shanghai 1
Taiyuan 1
Tianjin 1
Toronto 1
Vienna 1
Zurich 1
Totale 386
Nome #
Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease? 113
Evidence-based medicine and the problem of healthy volunteers 84
Nutrition in patients with type 2 diabetes: Present knowledge and remaining challenges 53
Obesity and NAFLD: Same problem? 52
Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real-world data analysis 47
NASH: A glance at the landscape of pharmacological treatment 46
Real-world prevalence of metabolic associated fatty liver disease (MAFLD) and fibrotic-non-alcoholic steatohepatitis (NASH) in patients with obesity (PwO) in an outpatient specialist clinic in Italy 43
Considerations when prescribing pharmacotherapy for metabolic associated fatty liver disease 34
Lifestyle Intervention in NAFLD: Long-Term Diabetes Incidence in Subjects Treated by Web- and Group-Based Programs 25
Association between Albumin Alterations and Renal Function in Patients with Type 2 Diabetes Mellitus 23
Real-life prevalence of Metabolic Associated Fatty Liver Disease (NAFLD) and non-alcoholic steatohepatitis (NASH) in a tertiary obesity clinic in Italy 21
Risk of binge eating disorder in patients with metabolic dysfunction-associated steatotic liver disease 9
Symptoms of SARS-CoV-2 infection and vaccine status of sixty-seven adult patients affected by inherited metabolic diseases: a phone survey 7
Burden of non-alcoholic fatty liver disease and usefulness of non-invasive tests to identify advanced liver disease in patients with type 2 diabetes mellitus: interimanalysis of an Italian prospective multicentre study 6
Caloric input is inadequate in predicting the presence of liver steatosis and fibrosis in a population adhering to a screening program for metabolic syndrome 5
Totale 568
Categoria #
all - tutte 2.492
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.492


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202063 0 2 0 2 9 7 11 9 14 2 2 5
2020/202127 8 3 2 0 0 0 5 0 4 2 0 3
2021/2022119 3 12 6 0 8 6 3 8 12 6 35 20
2022/2023156 9 13 6 12 16 8 11 7 39 7 12 16
2023/2024138 16 14 6 4 10 19 2 10 6 27 11 13
2024/202519 17 2 0 0 0 0 0 0 0 0 0 0
Totale 568